Skip to main content
Premium Trial:

Request an Annual Quote

PLOS Papers on Adverse Drug Reaction GWAS, Rare Variant Gene Regulators, Ovarian Cancer MicroRNAs

In PLOS Genetics, researchers from Vanderbilt University Medical Center and elsewhere outline findings from a genome-wide association study on adverse drug reactions (ADR) to common drugs or drug group representatives. Using array-based genotyping profiles, imputed genotyping clues, and drug allergy insights in electronic health record (EHR) data for more than 81,700 Vanderbilt BioVU DNA Biobank participants of European or African ancestry, the team narrowed in on seven loci linked to ADRs for 14 commonly prescribed drugs or drug types in European individuals — a set that encompassed variants in genes previously linked to adverse responses to opioid drugs such as CYP2D6 and OPRM1. From these and other results, the authors suggest that the high-throughput approach used "can enable impactful pharmacogenomic research to help develop clinical guidelines for the delivery of the right drug to the right person."

A team from the US and Korea documents rare variants with apparent ties to gene expression regulation across dozens of human tissue types for another paper in PLOS Genetics. With the help of an analytical approach called a "likelihood ratio test for quantitative traits" (LRT-q), the investigators analyzed whole-genome sequence and RNA sequence data spanning samples from 49 tissue types in nearly 700 Genotype-Tissue Expression (GTEx) project participants of European ancestry, highlighting genes with particularly pronounced expression patterns or disease associations that appeared to be regulated by rare rather than common variants. "These results demonstrate the functional effects of rare variants, especially on gene expression," they report, "which provides important biological insights in understanding the genetic mechanism of rare variants in complex traits and diseases."

For a paper appearing in PLOS One, a team from Denmark explores microRNA expression profiles in epithelial ovarian cancer, in an effort to find potential miRNA markers of disease stage, treatment response, or patient outcomes. Based on array-based miRNA analyses of epithelial ovarian cancer samples from almost 200 participants in the Pelvic Mass study from 2004 to 2010, the researchers focused in on a miRNA called miR-130a that appeared to coincide with more advanced epithelial ovarian cancer cases and with the presence of serous tumor histology, while flagging a handful of other miRNAs that were associated with other clinical or pathological tumor features. "This study continues our work to advance the knowledge of miRNA as a biomarker for clinical outcomes in [ovarian cancer]," the authors write, concluding that miR-130a "may be of prognostic importance for patients with [epithelial ovarian cancer]," though miRNA profiling studies in larger ovarian cancer groups are needed.

The Scan

Aducanumab?Approval

The US Food and Drug Administration has approved aducanumab, an Alzheimer's disease treatment, despite concerns it might not be effective, NPR reports.

Can Take Part

The Guardian writes that the European Commission no longer plans to prevent the UK from participating in certain space and supercomputing projects.

Keeping Up

The Atlantic writes that SARS-CoV-2 tests may have to change to keep up as new variants arise.

PNAS Papers on MERS-CoV in Africa, Ancient Goat Domestication, Cell Cycle Checkpoint

In PNAS this week: analysis of MERS-CoV clades in Africa, ancient genomes give insight into goat domestication, and more.
123